New research reveals that certain brain tumors may originate silently within normal brain cells long before a tumor forms.

IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young ...

IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young adults under the age of 50.

New research has shown how brain cells acquire a cancerous mutation and spread across the cortex, opening a new path for ...

Brain cancer is difficult to treat when it starts growing, and a prevalent type, known as a glioma, has a poor five-year survival rate. In a new study, researchers report on a new surgical platform ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first approval of ...

For patients with higher-grade or progressive IDH -mutant glioma, how do you individualize choice between radiotherapy (RT) ...

Treatment with vorasidenib significantly improved progression free survival compared with placebo. The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib) for the treatment of adult ...

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 ...